Si-Han Liu

Si-Han Liu

Auto-generated profile, based on publicly available information

Si-Han Liu

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2025 in British Journal of Dermatology
Verified
Journal Article
Closed access
SWSi-Hang Wang
Si-Hang Wang
SLSi-Han Liu
Si-Han Liu
SLSi-Zhe LI
Si-Zhe LI
YZYa-Gang Zuo
Ya-Gang Zuo
Telitacicept, a TACI-Fc fusion that neutralizes BAFF/APRIL, was administered weekly (160 mg) to two women with pemphigus foliaceus who declined systemic corticosteroids and conventional immunosuppressants. Rapid disease control ensued (Pemphigus Disease Area Index score of 0 by weeks 8–10) with normalized anti-Dsg1 titres and sustained remission over 6 months; treatment was well tolerated without interruption. These preliminary observations, which represent, to our knowledge, the first use of telitacicept in pemphigus foliaceus, support BAFF/APRIL blockade as a potential steroid-sparing strategy.